Search results for "Neoplasms"

showing 10 items of 7988 documents

When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers.

2019

Near-triploid human tumors are frequently resistant to radio/chemotherapy through mechanisms that are unclear. We recently reported a tight association of male tumor triploidy with XXY karyotypes based on a meta-analysis of 15 tumor cohorts extracted from the Mitelman database. Here we provide a conceptual framework of the digyny-like origin of this karyotype based on the germline features of malignant tumors and adaptive capacity of digyny, which supports survival in adverse conditions. Studying how the recombinatorial reproduction via diploidy can be executed in primary cancer samples and HeLa cells after DNA damage, we report the first evidence that diploid and triploid cell sub-populati…

0301 basic medicineMalelcsh:QH426-470DNA repairKaryotypeSpindle ApparatusDigynyBiologyGenomeGermline03 medical and health sciencesnear-triploid cancer0302 clinical medicineMeiosisNeoplasmsGeneticsTumor Cells Culturedtumor blastomeresHumansGeneGenetics (clinical)GeneticsChromosomes Human XChromosomes Human YModels Geneticfungifood and beverageschemoresistancereprogrammingKaryotypeConcept Papertripolar mitosisTriploidyradioresistancelcsh:GeneticsMeiosis030104 developmental biologyGerm Cellspedogamy030220 oncology & carcinogenesisNeoplastic Stem Cellspolynuclear cancer cellsPloidyHeLa CellsdigynyGenes
researchProduct

MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.

2018

Background Lung inflammation in COPD is poorly controlled by inhaled corticosteroids (ICS). Strategies to improve ICS efficacy or the search of biomarkers who may select those patients candidates to receive ICS in COPD are needed. Recent data indicate that MUC1 cytoplasmic tail (CT) membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis. The objective of this work was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in COPD in vitro and in vivo models. Methods MUC1-CT expression was measured by real time PCR, western blot, immunohistochemistry and immunofluorescence. The inflammatory mediators IL-8, MMP9, GM-CSF and MIP3α were measured by EL…

0301 basic medicineMalemedicine.drug_classDrug ResistanceInflammationMUC1Corticosteroid resistancedigestive system03 medical and health sciencesMicePulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoid receptorIn vivoAdrenal Cortex HormonesmedicineAnimalsHumansGene Silencingskin and connective tissue diseasesneoplasmsDexamethasoneMUC1Agedlcsh:RC705-779Mice KnockoutCOPDLungbusiness.industryResearchChronic obstructive pulmonary diseaseMucin-1Sputumlcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseasedigestive system diseasesrespiratory tract diseasesMice Inbred C57BL030104 developmental biologymedicine.anatomical_structure030228 respiratory systemImmunologyCorticosteroidFemalemedicine.symptombusinessBiomarkersmedicine.drugRespiratory research
researchProduct

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or l…

2019

Abstract Background Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. Patients and methods Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients …

0301 basic medicineMalemedicine.medical_specialtyCLDN18.2Drug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsNauseagastro-oesophageal junction adenocarcinomaMedizinAdenocarcinomaGastroenterology03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGastrointestinal TumorsmedicineHumansProgression-free survivalAgedbusiness.industryStomachgastric cancerCancerAntibodies MonoclonalHematologyOriginal ArticlesMiddle Agedmedicine.diseaseddc:IMAB362030104 developmental biologymedicine.anatomical_structureTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisCohortVomitingAdenocarcinomaFemaleEsophagogastric Junctionmedicine.symptomzolbetuximabNeoplasm Recurrence Localbusiness
researchProduct

Pulmonary Strongyloides stercoralis infection.

2016

0301 basic medicineMalemedicine.medical_specialtyFatal outcomeEndemic DiseasesLung Diseases Parasiticmedicine.medical_treatment030106 microbiologySplenectomyMEDLINEGastroenterologyStrongyloides stercoralis03 medical and health sciencesImmunocompromised Host0302 clinical medicineFatal OutcomeX ray computedGastrectomyStomach NeoplasmsInternal medicineOccupational ExposuremedicineAnimalsHumansAged 80 and overbiologybusiness.industryMediterranean RegionSmokingGeneral Medicinebiology.organism_classificationAgricultural Workers' Diseases030228 respiratory systemSplenectomyStrongyloidiasisGastrectomyOccupational exposureEndemic diseasesbusinessStrongyloides stercoralisTomography X-Ray ComputedArchivos de bronconeumologia
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Patients with advanced oral squamous cell carcinoma have high levels of soluble E-cadherin in the saliva

2017

Background: The objective of this study was to assess the potential clinical value of the concentration of soluble salivary E-cadherin (sE-cadherin) compared with the clinical value of the resence of membranous E-cadherin (mE-cadherin) in oral squamous cell carcinoma tumor tissues. Material and Methods: Data regarding patient demographics, clinical stage, saliva and tumor tissue samples were collected. The saliva was analyzed for sE-cadherin protein levels and was compared to the mE-cadherin immunohistochemical expression levels in tumor tissues, which were assessed via the HercepTest® method. Patients without cancer were included in the study as a control group for comparisons of the sE-ca…

0301 basic medicineMalemedicine.medical_specialtySalivaE-cadher.inDiseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansStage (cooking)SalivaGeneral DentistryLymph nodeNeoplasm StagingOral Medicine and PathologyCadherinbusiness.industryResearchOral cancerCancerMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Cadherins030104 developmental biologymedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellImmunohistochemistrySurgeryFemaleMouth Neoplasmsbusiness
researchProduct

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Dif…

2018

AbstractAimsRelatively little is known about the health outcomes associated with very low plasma concentrations of high-density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We, therefore, investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study.Methods and resultsAnalysis was based on 21 751 participants from the REGARDS study who wer…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPhysiologyDown-RegulationCoronary Disease030204 cardiovascular system & hematologyRisk AssessmentWhite People03 medical and health sciences0302 clinical medicineSex FactorsRisk FactorsPhysiology (medical)Internal medicineCause of DeathNeoplasmsmedicineHumansLongitudinal StudiesStrokeCause of deathAgedDyslipidemiasCancer Death Ratebusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceHazard ratioCholesterol HDLHealth Status DisparitiesMiddle AgedProtective Factorsmedicine.diseaseConfidence intervalUnited StatesResidual riskBlack or African AmericanStroke030104 developmental biologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular research
researchProduct

Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus.

2018

Previous studies indicate a role of CDKN2A/2B/2BAS genes in atherosclerosis and type 2 diabetes mellitus (T2DM). Progression of these diseases is accompanied by T-cell imbalance and chronic inflammation. Our main objective was to investigate a potential association between CDKN2A/2B/2BAS gene expression and T cell phenotype in T2DM and coronary artery disease (CAD) in humans, and to explore the therapeutic potential of these genes to restore immune cell homeostasis and disease progression. Reduced mRNA levels of CDKN2A (p16Ink4a), CDKN2B (p15Ink4b), and CDKN2BAS were observed in human T2DM and T2DM-CAD subjects compared with controls. Protein levels of p16Ink4a and p15Ink4b were also dimini…

0301 basic medicineMalemedicine.medical_specialtyendocrine system diseasesMice Knockout ApoECD3T cellCD14Inflammation03 medical and health sciencesMice0302 clinical medicinePhysiology (medical)Internal medicineNeointimamedicineAnimalsHumansIL-2 receptorInterleukin-7 receptorneoplasmsbiologybusiness.industryGenes p16Biochemistry (medical)CDKN2BASPublic Health Environmental and Occupational HealthType 2 Diabetes MellitusGeneral MedicineAtherosclerosis030104 developmental biologyEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 2030220 oncology & carcinogenesisbiology.proteinLeukocytes Mononuclearmedicine.symptombusinessTranslational research : the journal of laboratory and clinical medicine
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Isoform-specific function of calpains in cell adhesion disruption: studies in postlactational mammary gland and breast cancer.

2016

Cleavage of adhesion proteins is the first step for physiological clearance of undesired cells during postlactational regression of the mammary gland, but also for cell migration in pathological states such as breast cancer. The intracellular Ca2+-dependent proteases, calpains (CAPNs), are known to cleave adhesion proteins. The isoform-specific function of CAPN1 and CAPN2 was explored and compared in two models of cell adhesion disruption: mice mammary gland during weaning-induced involution and breast cancer cell lines according to tumor subtype classification. In both models, E-cadherin, β-catenin, p-120, and talin-1 were cleaved as assessed by western blot analysis. Both CAPNs were able …

0301 basic medicineMammary glandBreast NeoplasmsProximity ligation assayBiochemistry03 medical and health sciencesMiceWestern blotmedicineCell AdhesionAnimalsHumansLactationInvolution (medicine)BreastCell adhesionMolecular Biologybiologymedicine.diagnostic_testCalpainCalpainCell migrationCell BiologyCytosol030104 developmental biologymedicine.anatomical_structurebiology.proteinCancer researchFemaleThe Biochemical journal
researchProduct